EXECUTIVE LEADERSHIP TEAM

Meet The Leukemia & Lymphoma Society's Executive Leadership Team

Officers

Louis J. DeGennaro, Ph.D.

Louis J. DeGennaro, Ph.D.

President and Chief Executive Officer

Louis J. DeGennaro, Ph.D., was named president and chief executive officer of the The Leukemia & Lymphoma Society (LLS), in September 2014. LLS is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.

DeGennaro has served as interim president and CEO of LLS since February 2014 and leads the operations of this $300 million cancer patient advocacy agency with headquarters in White Plains, New York.

DeGennaro has been a critical member of the LLS executive leadership team since he joined LLS in 2005. He is recognized as the key architect of LLS's cures and access agenda to help save lives of blood cancer patients and the LLS Therapy Acceleration Program® - a venture philanthropy endeavor that defined the role of nonprofit organizations in supporting drug discovery and development with the biotechnology industry. He was named LLS chief mission officer in 2009, with responsibility for leadership of LLS's mission functions of research, patient access, education, public policy and advocacy.

DeGennaro has more than 25 years of research, drug development and executive management experience in academic and private sector settings. He received his doctorate in biochemistry from the University of California at San Francisco and did his post-doctoral research at the Yale University School of Medicine.  His previous academic appointments include research group leader, Max Planck Institute in Munich, Germany, where his laboratory was among the first to clone genes expressed exclusively in the nervous system; and associate professor of neurology and cell biology, University of Massachusetts Medical School.

DeGennaro's private-sector positions include: senior director of molecular genetics at Wyeth Pharmaceuticals, Princeton, N.J., where his department contributed to the development of pantoprazole (Protonix®) to treat acid reflux disease, Effexor (Venlafaxine®) for anxiety and depression and Mylotarg® for leukemia; executive vice president for research and development, SynX Pharma, Inc. in Toronto, Canada, where he was responsible for the development of a point-of-care diagnostic test for congestive heart failure; and research manager at Streck, Inc., Omaha, Neb., where he helped develop an FDA-cleared diagnostic test for AIDS/HIV.

DeGennaro was appointed by the U.S. Secretary of Health and Human Services in 2012 to serve as a member of the National Center for Advancing Translational Sciences Advisory Council, and the Cures Acceleration Network Review Board at the National Institutes of Health (NIH). He also serves on the Boards of BioTheryX, Inc., an early-stage biotechnology company and the Health Research Alliance, an alliance of non-profit funders of research.

Rosemarie Loffredo

Rosemarie Loffredo

Chief Administrative Officer and Chief Financial Officer

In her role as chief administrative officer and chief financial officer, Rosemarie Loffredo ensures that LLS achieves the ambitious goals of its long-range strategic plan. Loffredo leads all administrative and staff functions, including finance, information technology and human resources, and she is responsible for enhancing LLS's organizational efficiency and effectiveness in partnership with the organization's executive team.
 
Earlier in her career, Loffredo served as interim chief financial officer for Pro Mujer International, a nonprofit organization dedicated to empowering disenfranchised women in Latin America through microfinance, healthcare and educational services. She previously served as vice president, financial operations and treasurer of New York University, the largest private research university in the U.S. She also served as senior vice president of finance for CA Technologies, Inc. (formerly Computer Associates), one of the world's largest enterprise management software providers and prior to that position was vice president of treasury for International Paper Company. She previously held leadership positions with global banks in international treasury as well industry segment management including securities and commodities, capital-intensive industry and public finance. Loffredo currently serves on the board of directors of CenterLight Healthcare System.

Loffredo holds a bachelor's degree in international economics, commerce and finance from Georgetown University, a master's degree in economics from Boston College, and an M.B.A in finance and international business from Columbia University.

Mark Roithmayr

Mark Roithmayr

Chief Development Officer

As chief development officer, Mark Roithmayr oversees LLS's donor development initiatives. Roithmayr comes to LLS with a successful track record in the health-care non-profit sector.

As president of Autism Speaks for the past seven years, Roithmayr oversaw the establishment and growth of the organization from start up to the leading autism organization it is in the U.S. today. Among his accomplishments was establishing their major gifts program, successfully stewarding six-, seven and eight-figure gifts. Prior to his tenure at Autism Speaks, he served for 20 years with March of Dimes Birth Defects Foundation, in White Plains, N.Y., in a number of senior-level capacities eventually being responsible for raising $220 million annually.

He earned a bachelor of arts in communications with a concentration in public relations from Rowan University, Glassboro, N.J